Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Strata Critical Medical (SRTAW) Tax Provisions (2019 - 2025)

Historic Tax Provisions for Strata Critical Medical (SRTAW) over the last 7 years, with Q2 2025 value amounting to $21000.0.

  • Strata Critical Medical's Tax Provisions fell 5961.54% to $21000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was -$251000.0, marking a year-over-year increase of 7620.85%. This contributed to the annual value of -$255000.0 for FY2024, which is 8260.57% up from last year.
  • According to the latest figures from Q2 2025, Strata Critical Medical's Tax Provisions is $21000.0, which was down 5961.54% from -$17000.0 recorded in Q1 2025.
  • In the past 5 years, Strata Critical Medical's Tax Provisions ranged from a high of $129000.0 in Q3 2023 and a low of -$3.6 million during Q3 2021
  • For the 5-year period, Strata Critical Medical's Tax Provisions averaged around -$482538.5, with its median value being -$109000.0 (2021).
  • As far as peak fluctuations go, Strata Critical Medical's Tax Provisions crashed by 1358314.3% in 2021, and later skyrocketed by 13035.71% in 2023.
  • Quarter analysis of 5 years shows Strata Critical Medical's Tax Provisions stood at -$109000.0 in 2021, then plummeted by 659.63% to -$828000.0 in 2022, then fell by 23.55% to -$1.0 million in 2023, then skyrocketed by 75.07% to -$255000.0 in 2024, then soared by 108.24% to $21000.0 in 2025.
  • Its Tax Provisions was $21000.0 in Q2 2025, compared to -$17000.0 in Q1 2025 and -$255000.0 in Q4 2024.